Flotetuzumab (MGD006; S80880) is a bispecific dual-affinity retargeting antibody (DART) that targets CD123 and CD3, designed for the treatment of acute myeloid leukemia (AML). This investigational molecule facilitates T-cell activation by concurrently engaging CD123 on target cells and CD3 on effector T cells. This interaction promotes T-cell-mediated cytotoxicity against the target cells. Efficacy studies, including those using a mouse model with patient-derived xenografts (PDX), have demonstrated flotetuzumab's potential to inhibit the progression of AML.
Flotetuzumab (MGD006; S80880) is a bispecific dual-affinity retargeting antibody (DART) that targets CD123 and CD3, designed for the treatment of acute myeloid leukemia (AML). This investigational molecule facilitates T-cell activation by concurrently engaging CD123 on target cells and CD3 on effector T cells. This interaction promotes T-cell-mediated cytotoxicity against the target cells. Efficacy studies, including those using a mouse model with patient-derived xenografts (PDX), have demonstrated flotetuzumab's potential to inhibit the progression of AML.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
